This site is intended for health professionals only
Sunday 25 February 2018
Share |

Topic: Infectious Disease

February 22, 2018
Vosevi® is the first single tablet regimen for patients who have previously failed therapy with direct-acting antivirals

Gilead Sciences has welcomed the Technology Appraisal Guidance (TAG) issued by the National Institute for Health and Care Excellence (NICE), which recommends Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg; SOF/VEL/VOX).1

 

January 31, 2018
Letermovir is a first-in-class antiviral drug that inhibits cytomegalovirus replication

MSD has announced that the European Commission (EC) has granted marketing authorisation for letermovir as an orphan medicinal product for prophylaxis (prevention) of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).1

 

January 12, 2018
Bezlotoxumab is the first EC licensed non-antibiotic option indicated to prevent Clostridium difficile infection recurrence in high-risk adults

MSD has announced the UK launch of Zinplava® (bezlotoxumab) - a new therapy for the prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.1

 

Bezlotoxumab is administered as a single, one-off, one-hour intravenous infusion alongside standard-of-care (SoC) antibiotic therapy for the treatment of CDI.1

 

November 15, 2017
For patients undergoing an allogeneic haematopoietic stem cell transplant, complications arising from cytomegalovirus infection can be life threatening

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of letermovir for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).1

 

July 21, 2017
Proven efficacy and durability of darunavir combined with the improved renal laboratory and bone mineral density profile of emtricitabine/tenofovir alafenamide fumarate as compared with emtricitabine/tenofovir disoproxil fumarate in single tablet

Janssen-Cilag International NV has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for darunavir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (D/C/F/TAF) (Symtuza), a new once-daily darunavir-based single tablet regimen (STR).

June 29, 2017
First and only option for acute bacterial skin and skin structure infections that offers a complete course of IV therapy delivered as a single 30-minute infusion

An intravenous antibiotic that could benefit patients and help reduce pressure on hospitals is now available in the UK.

 

Xydalba™ (dalbavancin hydrochloride) is an IV antibiotic approved by the European Medicines Agency (EMA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. It is the first and only option for ABSSSI that offers a complete course of IV therapy delivered as a single 30-minute infusion.

 

May 5, 2017
CDI, a potentially fatal disease, is three times as deadly as MRSA and is estimated to cost the EU €3 billion per annum

Data presented  at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, demonstrate benefits of extended-pulsed fidaxomicin (EPFX), compared to standard vancomycin.1
 

March 8, 2016
Universities of Dundee (Scotland), & Cape Town (South Africa) partnering with Bayer (Germany)

World-leading medicinal chemistry and biology at the Universities of Dundee (Scotland) and Cape Town (South Africa) have been allied to the industrial expertise of the Pharmaceuticals Division of Bayer (Germany), one of the world’s leading pharma companies, in an effort to develop critically needed new treatments for tuberculosis (TB).
 

November 19, 2015
Investigational HCV regimen with ABT-493 and ABT-530 evaluating a pan-genotypic, once-daily treatment option with shorter duration of therapy
August 19, 2015
Antibiotic Research UK will announce at its Annual General meeting its first research programme to tackle antibiotic resistant bacteria (superbugs)
August 10, 2015
This article covers antiretroviral therapy, aims of treatment and when to start therapy, resistance, management of toxicities, adherence, and current and future treatment strategies

 

August 7, 2015
In a busy London tertiary hospital I start my day by replying to any urgent emails relating to antimicrobials

In a busy London tertiary hospital I start my day by replying to any urgent emails relating to antimicrobials.  At the moment I am coordinating the quarterly antimicrobial prescribing audits with the pharmacy department ensuring that the data is collected within the two week period, before analysing the data to produce a report on how different medical areas are complying with set measured criteria.

 

July 9, 2015
Zevtera® (Ceftobiprole medocaril): the latest generation Cephalosporin with broad-spectrum of activity launches in the UK
June 24, 2015
Tuberculosis sufferers will be able get drug treatment sooner thanks to a new whole genome sequencing technique

Tuberculosis sufferers will be able get drug treatment sooner thanks to a new whole genome sequencing technique to determine for the first time which drugs to give sufferers, researchers in Oxford have reported.

 

University of Oxford researchers at the John Radcliffe Hospital have developed a genetic test – details of which are published online in the Lancet Infectious Diseases – that can detect which drugs will effectively treat people with the disease and those that will not.

 

June 10, 2015
More than 200,000 people in the UK are chronically infected with hepatitis C, (1) of which only an estimated 3% are treated each year, despite the advent of treatments that can offer viral elimination. (1)

More than 200,000 people in the UK are chronically infected with hepatitis C, (1) of which only an estimated 3% are treated each year, despite the advent of treatments that can offer viral elimination. (1)

May 19, 2015
Data presented from the CDI Service Evaluation study shows that the adoption pattern of treatment impacts CDI outcomes. Compared to traditional broad-spectrum antibiotics, first-line use of fidaxomicin, a targeted treatment, in all CDI patients provides improved outcomes in terms of recurrence rate, all-cause mortality and cost effectiveness, compared to use in selected patients only. (8) CDI is associated with high-mortality (5,6,7) and cost burden, (9) therefore reducing the incidence and recurrence of CDI is a priority for clinicians, payers and health authorities alike.
May 11, 2015
This could help health service providers to better treat disease, control transmission of this infection, and monitor outbreaks. Tuberculosis (TB) disease rates in some parts of London are as high as in Sub-Saharan Africa, and drug-resistant strains are becoming increasingly common. These require specific treatments, and if doctors know that a bug is resistant they can start therapy earlier, often leading to better outcomes.

This could help health service providers to better treat disease, control transmission of this infection, and monitor outbreaks. Tuberculosis (TB) disease rates in some parts of London are as high as in Sub-Saharan Africa, and drug-resistant strains are becoming increasingly common. These require specific treatments, and if doctors know that a bug is resistant they can start therapy earlier, often leading to better outcomes.

April 29, 2015
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announced breaking developments in the global fight against infections – with new mechanisms and approaches presented by smaller companies in a dedicated pipeline session at the annual congress (ECCMID) in Copenhagen.

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announced breaking developments in the global fight against infections – with new mechanisms and approaches presented by smaller companies in a dedicated pipeline session at the annual congress (ECCMID) in Copenhagen.
 
Ursula Theuretzbacher, the founder of the Centre for Anti-Infective Agents in Vienna, led the session, which gave a review of the research and development programmes from across some of the most innovative and nimble European biotech companies.

April 21, 2015
The European Society of Clinical Microbiology and Infectious Disease (ESCMID) – an organisation that explores risk assessment, knowledge sharing and best practices in the fight against infectious disease – has warned that Britain and Europe collectively could face more than a million deaths in an impending "Antibiotic Armageddon” unless more is done to develop new cures, rapid diagnostics and preventative measures to combat the spread of drug resistant diseases.

The European Society of Clinical Microbiology and Infectious Disease (ESCMID) – an organisation that explores risk assessment, knowledge sharing and best practices in the fight against infectious disease – has warned that Britain and Europe collectively could face more than a million deaths in an impending "Antibiotic Armageddon” unless more is done to develop new cures, rapid diagnostics and preventative measures to combat the spread of drug resistant diseases.

March 19, 2015
The European Society for Clinical Microbiology and Infectious Diseases (ESCMID) has been joined by the World Health Organisation (WHO) to launch the 7th annual ‘International Day for Fighting Infection’ (24 April 2015). This year’s event sees the European society exploring vaccines as a possible solution in the global, cross-border fight against antimicrobial resistance.

The European Society for Clinical Microbiology and Infectious Diseases (ESCMID) has been joined by the World Health Organisation (WHO) to launch the 7th annual ‘International Day for Fighting Infection’ (24 April 2015).  This year’s event sees the European society exploring vaccines as a possible solution in the global, cross-border fight against antimicrobial resistance.
 

February 25, 2015
Researchers from the Medical Research Council Clinical Trials Unit (MRC CTU) and Public Health England have presented results at a conference in Seattle, Washington, indicating that pre-exposure prophylaxis (PrEP) is highly protective against HIV for gay and other men who have sex with men in England.

Researchers from the Medical Research Council Clinical Trials Unit (MRC CTU) and Public Health England have presented results at a conference in Seattle, Washington, indicating that pre-exposure prophylaxis (PrEP) is highly protective against HIV for gay and other men who have sex with men in England.

 

February 16, 2015
A retrospective investigation on hospitalised patients with Clostridium difficile showed the importance of clinical pharmacy services in reducing the length of hospital stay

 

February 16, 2015
Combination antiretroviral therapy is recommended as first-line treatment for HIV and developments in dolutegravir-based regimens are discussed in this article

 

February 16, 2015
Sepsis is a time-critical condition that requires prompt recognition and rapid initiation of treatment and pharmacists need to be able to recognise the deteriorating patient and ensure appropriate treatment

 

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine